AJMC Staff

Articles by AJMC Staff

The FDA Tuesday cleared a new dose of Samsung Bioepis’ trastuzumab biosimilar Ontruzant, which is yet to be launched in the United States. The approval is for a 420-mg multidose vial of Ontruzant. The biosimilar was first approved as a 150-mg single-dose vial by the FDA in January 2019 across all indications for the reference product, Herceptin.

The International Olympic Committee postpones the 2020 games slated for this summer; the American Society of Clinical Oncology (ASCO) urges Congress for increased protection and support for medical practices; AHIP will allow its member payers to transfer patients with coronavirus disease 2019 (COVID-19) from hospitals to other clinical settings, if appropriate, without prior authorization.

Nurses are voicing their concern about the lack of protective gear in caring patients with or suspected of having COVID-19; the FDA warned that new at-home tests in the marketplace for coronavirus disease, which is caused by severe acute respiratory syndrome coronavirus, have not been approved; US jails and prison systems have begun to allow the release of inmates who have commited petty crimes and those potentially at-risk of severe COVID-19 infection.

Two studies discussed the feasibility of different parameters for the infusion of a product for patients with primary immunodeficiency disorder in abstracts prepared for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting.

The Trump administration asked Congress for billions in COVID-19 assistance for Americans while a report said government responses in both the United States and the United Kingdom were suddenly being influenced by a grim analysis forecasting half a million to over 2 million deaths if the virus is allowed to run rampant without nonpharmaceutical interventions—ie, social isolation.

Included among the abstracts prepared and published for the American Academy of Allergy, Asthma & Immunology 2020 Annual Meeting are several that looked at the clinical and psychosocial factors that complicate asthma in pediatric patients. A few are highlighted here.



Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo